Salman Fazal, MD, Receives 2026 Castle Connolly Top Doctor Designation for Hematology Practice

Salman Fazal, MD, a hematologist based at the UPMC Hillman Cancer Center, has been named a 2026 Castle Connolly Top Doctor for the third consecutive year. This recognition is awarded annually to approximately seven percent of licensed physicians in the United States based on peer nominations and research conducted by the organization. Dr. Fazal focuses on treating complex hematologic conditions, including various forms of leukemia and lymphoma, while managing programs dedicated to stem cell transplantation and cellular therapy for patients in Central Pennsylvania.

The Castle Connolly designation process relies on peer-based nominations and a research team that evaluates candidates based on medical training, hospital affiliations, and disciplinary history. By highlighting individual practitioners who meet these specific criteria, the industry maintains a framework for identifying physicians who have achieved recognized benchmarks in their respective fields. For hematology and oncology, this process provides a standardized method of acknowledgement that is independent of commercial influence, as the organization explicitly prohibits payment for inclusion in its Top Doctor listings.

Dr. Fazal’s recognition reflects the broader focus on specialty care within the healthcare sector, particularly regarding the management of high-risk malignant hematologic conditions. His work in stem cell transplantation and cellular therapy, including the administration of bispecific antibodies, illustrates the current medical emphasis on targeted treatments for patients who do not respond to conventional chemotherapy protocols. As clinical research continues to evolve, the ability of practitioners to translate findings from phase II and phase III trials into direct patient care remains a critical component of institutional success. The focus on long-term follow-up and clinical trial access for conditions like graft-versus-host disease highlights the ongoing requirements for specialized infrastructure in managing complex oncological patients. These roles are essential for maintaining accreditation standards and ensuring that clinical programs meet expected survival benchmarks within the competitive landscape of modern academic and community-based oncology centers.